Scoping Review on ADCY5-Related Movement Disorders.
Poornima Jayadev MenonChristelle NillesLaura Silveira-MoriyamaRuiyi YuanClaudio M De GusmaoAlexander MünchauMiryam CarecchioSteve GrossmanGay GrossmanAurélie MéneretEmmanuel RozeTamara M PringsheimPublished in: Movement disorders clinical practice (2023)
The current evidence for therapeutic options for ADCY5-RMD is limited: caffeine, benzodiazepines and deep brain stimulation have been consistently reported to be useful in case reports and case series.